A. Qin

发表

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Robin L. Jones, G. Schwartz, W. Tap, 2016, The Lancet.

Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

Gaurav, Robin L. Jones, G. Schwartz, 2017 .

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).

Robin L. Jones, G. Schwartz, W. Tap, 2015 .

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

N. Shire, E. Smit, D. Camidge, 2022, ESMO open.

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

M. Saif, E. Chiorean, J. Kauh, 2016, Cancer Chemotherapy and Pharmacology.

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

P. Rutkowski, P. Hohenberger, J. Nippgen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

D. Gerber, P. Swanson, A. Dowlati, 2017, Lung cancer.

Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

W. Schultze‐Seemann, J. Nippgen, B. Sautois, 2019, European journal of cancer.

A Phase II Study of a Human Anti-PDGFRα Monoclonal Antibody (Olaratumab, IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors.

P. Rutkowski, P. Hohenberger, J. Nippgen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

J. Nippgen, R. Amato, E. Chiorean, 2014, Cancer Chemotherapy and Pharmacology.

LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen

J. Ajani, E. Van Cutsem, Z. Wainberg, 2021, Annals of Oncology.

Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies

H. Iwata, E. Smit, C. Fuchs, 2021, Clinical Trials.

1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

J. Ajani, E. Van Cutsem, G. Ku, 2022, Annals of Oncology.

92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

H. Iwata, C. Powell, S. Verma, 2021 .

289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies

D. Camidge, S. Modi, Jasmeet Singh, 2020 .

P01A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts)

Robin L. Jones, G. Schwartz, W. Tap, 2016 .

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

A. Tolcher, A. Patnaik, M. Mita, 2007 .

Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).

E. Chiorean, J. Kauh, B. O'Neil, 2015 .

Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.

L. Benjamin, R. Martell, E. Chiorean, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

J. Ajani, E. Van Cutsem, G. Ku, 2023, The Lancet. Oncology.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

D. Gerber, P. Swanson, A. Dowlati, 2017, Lung cancer.